Although treatment of acromegaly with the GH receptor (GHR) antagonist pegvisomant achieves a high rate of long-term biochemical control and can improve acromegaly comorbidities [11-14], little is known about its effects on the bone disease of acromegaly. Here, GHR is linked to acromegaly.